AV
Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
$5.23 -1.32% (-$0.07)
1M +0.19%
Market Cap $418.5M
P/E Ratio -
Div. Yield -
ROE 64.25%
Bulios Fair Price
$2.95
43.6% downside
Current Price
$5.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AVIR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
86 /100
Cheap P/B 2.05x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 24.52%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 86.35%
ROE 64.25%
ROA 71.16%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 8.13x
Int. coverage N/A
Stability
51 /100
Moderate Beta 0.29x
EPS volatility 13.54%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AVIR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jean-Pierre Sommadossi
Employees
55
Headquarters
Boston
Upcoming events
11 NOV
Earnings
Upcoming earnings report